Breaking News Instant updates and real-time market news.

MRK

Merck

$84.31

0.6 (0.72%)

, JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

15:49
10/13/19
10/13
15:49
10/13/19
15:49

Congo to start using Johnson & Johnson Ebola vaccine next month, Reuters says

Health authorities in Democratic Republic of Congo will introduce a Johnson & Johnson (JNJ) Ebola vaccine in November in the country's eastern provinces, to counter the current outbreak, according to Reuters. The J&J vaccine will complement another vaccine manufactured by Merck (MRK), which has been administered to more than 225,000 people, the publication adds. Reference Link

MRK

Merck

$84.31

0.6 (0.72%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

  • 15

    Oct

  • 23

    Oct

  • 29

    Oct

  • 06

    Nov

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

MRK Merck
$84.31

0.6 (0.72%)

09/18/19
RHCO
09/18/19
NO CHANGE
Target $14
RHCO
Hold
Lannett price target raised to $14 from $10 at SunTrust
SunTrust analyst Gregg Gilbert raised his price target on Lannett (LCI) to $14, adjusting his model to reflect its potentially significant opportunity with the recent launch of posaconazole - a generic version of Merck's (MRK) Noxafil. The analyst notes that he now models sales and EBITDA at the higher end of the company's FY20 targets while also raising his FY20 EPS view by 19c to $1.33. Gilbert still keeps his Hold rating on the stock, citing the uncertainty around Lannett's capital structure and limited pipeline visibility as well as the challenging environment for generics.
09/30/19
GUGG
09/30/19
INITIATION
Target $12
GUGG
Buy
Guggenheim starts Bellus Health at Buy with $12 price target
As previously reported, Guggenheim analyst Dana Flanders initiated Bellus Health (BLU) with a Buy rating and $12 price target. BLU-5937 for refractory chronic cough is the primary value driver in "a potential multi-billion dollar category," said Flanders, who also sees the opportunity for label expansion and the potential for M&A interest in Bellus. Merck (MRK) acquired Afferent, which also has a P2X3 antagonist asset called gefapixant, in 2016 for $500M upfront and up to $1.25B with milestones, noted Flanders.
09/30/19
JPMS
09/30/19
NO CHANGE
JPMS
Neutral
Competitor PARP data an incremental negative for Clovis, says JPMorgan
JPMorgan analyst Cory Kasimov said he views the Phase 3 data presented by AstraZeneca (AZN) and Merck (MRK) on their PARP inhibitor Lynparza in previously treated prostate cancer as incrementally negative to Clovis (CLVS), which has "a lot riding on the prostate indication" since its Rubraca is "neck-and-neck with the competition to be first to market." While there wasn't anything bad reported at the ESMO meeting from Clovis' own prostate update, AstraZeneca "looks primed to come to market with a much more robust data set" and Clovis may "be playing catch-up" in another cancer indication, said Kasimov, who keeps a Neutral rating on Clovis shares.
10/10/19
JPMS
10/10/19
NO CHANGE
Target $96
JPMS
Overweight
JPMorgan analysis indicates 'highly inexpensive valuation' for Merck
Investor sentiment on Merck shares remains positive but relative valuation and Keytruda concentration remains the primary pushback on the thesis, JPMorgan analyst Chris Schott tells investors in a research note. However, the analyst's sum-of-the-parts valuation analysis indicates a "highly inexpensive valuation" when incorporating a premium for the company's Animal health and Vaccines franchises. Further, while Keytruda represents a sizable portion of Merck's earnings and growth, the company has a full decade to further develop its pipeline and next-generation product offerings before the product faces biosimilar competition, Schott contends. As such, he continues to see Merck as one of the best positioned names in his coverage group. The analyst keeps an Overweight rating on the shares with a $96 price target.
JNJ Johnson & Johnson
$131.35

2.32 (1.80%)

08/27/19
FBCO
08/27/19
NO CHANGE
Target $156
FBCO
Outperform
Opioid ruling reduces uncertainty, helps J&J move higher, says Credit Suisse
Credit Suisse analyst Matt Miksic notes that Johnson & Johnson appeared to react favorably to Oklahoma opioid ruling, due in part, to the $572M penalty being substantially lower than the $17B sought by State prosecutors. The analyst believes the decision helped reduce the range of uncertainty related to the potential opioid-related liability Johnson & Johnson could face, specifically in Oklahoma, if not across the U.S. more broadly. Miksic reiterates an Outperform rating and $156 target on the shares.
10/02/19
WELS
10/02/19
NO CHANGE
WELS
Outperform
J&J Ohio settlements suggest 'manageable' liability, says Wells Fargo
Wells Fargo analyst Larry Biegelsen notes that Johnson & Johnson has announced a settlement agreement with the Ohio counties of Cuyahoga and Summit that resolves all of the counties' claims with no admission of liability and removes the company from the federal trial scheduled to begin October 21, 2019 for a total of $20.4M. The analyst notes that after applying the total settlement amount to the populations of Cuyahoga and Summit counties and that to the total U.S. population of 327M, he arrives at a total settlement amount of $3.7B, which is well below his expected total settlement amount of $10B-$15B. Importantly, Biegelsen expects any settlement amount to be paid over a period of many years which will make the potential payments more manageable for Johnson & Johnson. He has an Outperform rating on the shares.
10/11/19
BERN
10/11/19
UPGRADE
BERN
Outperform
Johnson & Johnson upgraded to Outperform from Market Perform at Bernstein
10/11/19
BERN
10/11/19
UPGRADE
Target $155
BERN
Outperform
Bernstein upgrades 'historically cheap' Johnson & Johnson to Outperform
Bernstein analyst Lee Hambright upgraded Johnson & Johnson to Outperform from Market Perform with a price target of $155, up from $148. The shares in premarket trading are up $1.94, or 1.5%, to $131. The stock is "historically cheap," currently trading at a 17% discount to its sum-of-the-parts and a 13% discount to the S&P 500 Index, Hambright tells investors in a research note. The analyst, who believes J&J will resolve its legal liability for $10B-$12B, says the shares reflect a worst case scenario with $50B of liabilities being priced in. Following discussions with legal experts, Hambright has a "hard time seeing the worst-case scenarios playing out." The analyst estimates Johnson & Johnson faces about $5B of liability for opioids, another $5B for talc, and $800M for Risperdal.

TODAY'S FREE FLY STORIES

AAPL

Apple

$263.19

-3.13 (-1.18%)

, SPX

S&P 500

$0.00

(0.00%)

17:35
11/20/19
11/20
17:35
11/20/19
17:35
Periodicals
Trump says considering whether to exempt Apple from China tariffs, Reuters says »

U.S. President Donald…

AAPL

Apple

$263.19

-3.13 (-1.18%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$310.82

-1.07 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$216.91

-1.26 (-0.58%)

17:28
11/20/19
11/20
17:28
11/20/19
17:28
Hot Stocks
Raytheon awarded $386M Air Force contract modification »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLH

Red Lion Hotels

$3.36

0.015 (0.45%)

17:23
11/20/19
11/20
17:23
11/20/19
17:23
Syndicate
Breaking Syndicate news story on Red Lion Hotels »

Red Lion Hotels files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KZIA

Kazia Therapeutics

$7.40

4 (117.65%)

17:20
11/20/19
11/20
17:20
11/20/19
17:20
Hot Stocks
Breaking Hot Stocks news story on Kazia Therapeutics »

Kazia Therapeutics Ltd…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$30.05

0.13 (0.43%)

17:14
11/20/19
11/20
17:14
11/20/19
17:14
Syndicate
Invitation Homes announces offering of 57.6M shares of common stock for holders »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UVV

Universal Corporation

$50.73

-0.84 (-1.63%)

17:08
11/20/19
11/20
17:08
11/20/19
17:08
Hot Stocks
Universal Corporation to acquire FruitSmart, terms not stated »

Universal Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBER

Uber

$28.02

0.99 (3.66%)

17:06
11/20/19
11/20
17:06
11/20/19
17:06
Hot Stocks
Breaking Hot Stocks news story on Uber »

Uber up 2.1% or 59c at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 04

    Dec

SBLK

Star Bulk Carriers

$10.04

-0.12 (-1.18%)

17:03
11/20/19
11/20
17:03
11/20/19
17:03
Earnings
Star Bulk Carriers reports Q3 EPS 18c, two estimates 17c »

Reports Q3 voyage revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

KRNY

Kearny Financial

$14.11

-0.08 (-0.56%)

17:01
11/20/19
11/20
17:01
11/20/19
17:01
Hot Stocks
Kearny Financial raises quarterly dividend to 7c from 6c per share »

Payable on December 20 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

L Brands

$16.00

-1.19 (-6.92%)

16:48
11/20/19
11/20
16:48
11/20/19
16:48
Hot Stocks
Breaking Hot Stocks news story on L Brands »

L Brands up 5.8% or 92c…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 05

    Dec

LVMUY

LVMH

$0.00

(0.00%)

, TIF

Tiffany

$123.32

-0.16 (-0.13%)

16:47
11/20/19
11/20
16:47
11/20/19
16:47
Periodicals
LVMH, Tiffany said to be in talks, Bloomberg says »

LVMH (LVMUY) is said to…

LVMUY

LVMH

$0.00

(0.00%)

TIF

Tiffany

$123.32

-0.16 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

LB

L Brands

$16.00

-1.19 (-6.92%)

16:46
11/20/19
11/20
16:46
11/20/19
16:46
Hot Stocks
L Brands backs FY19 free cash flow forecast at ~$750M »

Cuts FY19 SSS view to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 05

    Dec

UBER

Uber

$28.02

0.99 (3.66%)

16:43
11/20/19
11/20
16:43
11/20/19
16:43
Hot Stocks
Uber CEO Dara Khosrowshahi buys almost $7M in company shares »

Uber CEO Dara…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 04

    Dec

AVVIY

Aviva

$0.00

(0.00%)

16:42
11/20/19
11/20
16:42
11/20/19
16:42
Downgrade
Aviva rating change  »

Aviva downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLLGY

Hella KGaA Hueck

$0.00

(0.00%)

16:42
11/20/19
11/20
16:42
11/20/19
16:42
Upgrade
Hella KGaA Hueck rating change  »

Hella GmbH upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEG

Key Energy

$0.30

0.0095 (3.32%)

16:40
11/20/19
11/20
16:40
11/20/19
16:40
Hot Stocks
Key Energy receives notice from NYSE regarding continued listing requirements »

Key Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLLGY

Hella KGaA Hueck

$0.00

(0.00%)

16:40
11/20/19
11/20
16:40
11/20/19
16:40
Upgrade
Hella KGaA Hueck rating change  »

Hella KGaA Hueck upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGHC

National General

$20.47

-0.43 (-2.06%)

16:39
11/20/19
11/20
16:39
11/20/19
16:39
Hot Stocks
National General approved to sell its Accident Health and Care Sweden unit »

National General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$126.37

15.51 (13.99%)

, LOW

Lowe's

$117.84

4.43 (3.91%)

16:38
11/20/19
11/20
16:38
11/20/19
16:38
On The Fly
Fly Intel: Wall Street's top stories for Wednesday »

Stocks were slumping a…

TGT

Target

$126.37

15.51 (13.99%)

LOW

Lowe's

$117.84

4.43 (3.91%)

GM

General Motors

$35.26

-1.13 (-3.11%)

FCAU

Fiat Chrysler

$15.00

-0.585 (-3.75%)

KNSA

Kiniksa

$8.95

1.97 (28.22%)

ALNY

Alnylam

$108.26

10.27 (10.48%)

URBN

Urban Outfitters

$24.41

-4.32 (-15.04%)

PDD

Pinduoduo

$31.37

-9.34 (-22.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 03

    Dec

  • 05

    Dec

  • 07

    Dec

  • 04

    Feb

TUWOY

Tullow Oil

$0.00

(0.00%)

16:37
11/20/19
11/20
16:37
11/20/19
16:37
Downgrade
Tullow Oil rating change  »

Tullow Oil downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKL

Markel

$1,126.21

1.26 (0.11%)

16:36
11/20/19
11/20
16:36
11/20/19
16:36
Hot Stocks
Markel executive chairman Alan Kirshner to retire »

Markel Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CP

Canadian Pacific

$236.41

-1.66 (-0.70%)

, FTAI

Fortress Transportation

$16.72

-0.01 (-0.06%)

16:35
11/20/19
11/20
16:35
11/20/19
16:35
Hot Stocks
Canadian Pacific to acquire Central Maine & Quebec Railway from Fortress »

Canadian Pacific (CP) and…

CP

Canadian Pacific

$236.41

-1.66 (-0.70%)

FTAI

Fortress Transportation

$16.72

-0.01 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLLS

Cellectis

$13.13

-0.14 (-1.06%)

16:34
11/20/19
11/20
16:34
11/20/19
16:34
Hot Stocks
Cellectis wins patent challenge in Europe for CRISPR-Cas9 gene editing method »

Cellectis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

L Brands

$16.00

-1.19 (-6.92%)

16:34
11/20/19
11/20
16:34
11/20/19
16:34
Hot Stocks
L Brands sees Q4 SSS 'about flat' »

Sees FY19 SSS "About…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 05

    Dec

TBNK

Territorial Bancorp

$30.63

-0.31 (-1.00%)

16:34
11/20/19
11/20
16:34
11/20/19
16:34
Hot Stocks
Territorial Bancorp declares special dividend of 50c per share »

Territorial Bancorp has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.